With the goal of discovering non-invasive biomarkers for early diagnosis of GC, we conducted a case-control study utilising urine samples from individuals with predominantly early GC vs. healthy control (HC).
Among urine samples from 372 patients, age- and sex-matched 282 patients were randomly divided into three groups: 18 patients in a discovery cohort; 176 patients in a training cohort and 88 patients in a validation cohort.
Among urinary proteins identified in the comprehensive quantitative proteomics analysis, urinary levels of TFF1 (uTFF1) and ADAM12 (uADAM12) were significantly independent diagnostic biomarkers for GC, in addition to Helicobacter pylori status. A urinary biomarker panel combining uTFF1, uADAM12 and H. pylori significantly distinguished between HC and GC patients in both training and validation cohorts. On the analysis for sex-specific biomarkers, this combination panel demonstrated a good AUC of 0.858 for male GC, whereas another combination panel of uTFF1, uBARD1 and H. pylori also provided a good AUC of 0.893 for female GC. Notably, each panel could distinguish even stage I GC patients from HC patients (AUC = 0.850 for males; AUC = 0.845 for females).
Novel urinary protein biomarker panels represent promising non-invasive biomarkers for GC, including early-stage disease.
Subscribe to Journal
Get full journal access for 1 year
only $20.79 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M. et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer 136, E359–E386 (2015).
Nashimoto, A., Akazawa, K., Isobe, Y., Miyashiro, I., Katai, H., Kodera, Y. et al. Gastric cancer treated in 2002 in Japan: 2009 annual report of the JGCA nationwide registry. Gastric Cancer 16, 1–27 (2013).
Uemura, N., Okamoto, S., Yamamoto, S., Matsumura, N., Yamaguchi, S., Yamakido, M. et al. Helicobacter pylori infection and the development of gastric cancer. N. Engl. J. Med. 345, 784–789 (2001).
Sturgeon, C. M., Duffy, M. J., Hofmann, B. R., Lamerz, R., Fritsche, H. A., Gaarenstroom, K. et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in liver, bladder, cervical, and gastric cancers. Clin. Chem. 56, e1–e48 (2010).
Iwasaki, H., Shimura, T. & Kataoka, H. Current status of urinary diagnostic biomarkers for colorectal cancer. Clin. Chim. Acta 498, 76–83 (2019).
Shimura, T., Iwasaki, H., Kitagawa, M., Ebi, M., Yamada, T., Yamada, T. et al. Urinary cysteine-rich protein 61 and trefoil factor 3 as diagnostic biomarkers for colorectal cancer. Transl. Oncol. 12, 539–544 (2019).
Iwasaki, H., Shimura, T., Yamada, T., Okuda, Y., Natsume, M., Kitagawa, M. et al. A novel urinary microRNA biomarker panel for detecting gastric cancer. J. Gastroenterol. 54, 1061–1069 (2019).
Shimura, T., Ebi, M., Yamada, T., Yamada, T., Katano, T., Nojiri, Y. et al. Urinary kallikrein 10 predicts the incurability of gastric cancer. Oncotarget 8, 29247–29257 (2017).
Shimura, T., Dagher, A., Sachdev, M., Ebi, M., Yamada, T., Yamada, T. et al. Urinary ADAM12 and MMP-9/NGAL complex detect the presence of gastric cancer. Cancer Prev. Res. (Philos.). 8, 240–248 (2015).
McShane, L. M., Altman, D. G., Sauerbrei, W., Taube, S. E., Gion, M. & Clark, G. M. Reporting recommendations for tumor marker prognostic studies. J. Clin. Oncol. 23, 9067–9072 (2005).
Vandenbroucke, J. P., von Elm, E., Altman, D. G., Gotzsche, P. C., Mulrow, C. D., Pocock, S. J. et al. Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration. Epidemiology 18, 805–835 (2007).
Sobin, L. H., Gospodarowicz, M. K. & Wittekind, C. TNM Classification of Malignant Tumours, 7th edn. (John Wiley & Sons, Inc., Hoboken, 2009).
Wong, W. M., Poulsom, R. & Wright, N. A. Trefoil peptides. Gut 44, 890–895 (1999).
Lefebvre, O., Chenard, M. P., Masson, R., Linares, J., Dierich, A., LeMeur, M. et al. Gastric mucosa abnormalities and tumorigenesis in mice lacking the pS2 trefoil protein. Science 274, 259–262 (1996).
Machado, J. C., Carneiro, F., Ribeiro, P., Blin, N. & Sobrinho-Simoes, M. pS2 protein expression in gastric carcinoma. An immunohistochemical and immunoradiometric study. Eur. J. Cancer 32A, 1585–1590 (1996).
Muller, W. & Borchard, F. pS2 protein in gastric carcinoma and normal gastric mucosa: association with clincopathological parameters and patient survival. J. Pathol. 171, 263–269 (1993).
Soutto, M., Belkhiri, A., Piazuelo, M. B., Schneider, B. G., Peng, D., Jiang, A. et al. Loss of TFF1 is associated with activation of NF-kappaB-mediated inflammation and gastric neoplasia in mice and humans. J. Clin. Invest. 121, 1753–1767 (2011).
Soutto, M., Chen, Z., Bhat, A. A., Wang, L., Zhu, S., Gomaa, A. et al. Activation of STAT3 signaling is mediated by TFF1 silencing in gastric neoplasia. Nat. Commun. 10, 3039 (2019).
Aikou, S., Ohmoto, Y., Gunji, T., Matsuhashi, N., Ohtsu, H., Miura, H. et al. Tests for serum levels of trefoil factor family proteins can improve gastric cancer screening. Gastroenterology 141, 837–845 (2011).
Dardaei, L., Shahsavani, R., Ghavamzadeh, A., Behmanesh, M., Aslankoohi, E., Alimoghaddam, K. et al. The detection of disseminated tumor cells in bone marrow and peripheral blood of gastric cancer patients by multimarker (CEA, CK20, TFF1 and MUC2) quantitative real-time PCR. Clin. Biochem. 44, 325–330 (2011).
Yamanari, T., Sugiyama, H., Tanaka, K., Morinaga, H., Kitagawa, M., Onishi, A. et al. Urine trefoil factors as prognostic biomarkers in chronic kidney disease. Biomed. Res. Int. 2018, 3024698 (2018).
Lebherz-Eichinger, D., Tudor, B., Ankersmit, H. J., Reiter, T., Haas, M., Roth-Walter, F. et al. Trefoil factor 1 excretion is increased in early stages of chronic kidney disease. PLoS ONE 10, e0138312 (2015).
Shimura, T., Kataoka, H., Ogasawara, N., Kubota, E., Sasaki, M., Tanida, S. et al. Suppression of proHB-EGF carboxy-terminal fragment nuclear translocation: a new molecular target therapy for gastric cancer. Clin. Cancer Res. 14, 3956–3965 (2008).
Shimura, T., Yoshida, M., Fukuda, S., Ebi, M., Hirata, Y., Mizoshita, T. et al. Nuclear translocation of the cytoplasmic domain of HB-EGF induces gastric cancer invasion. BMC Cancer 12, 205 (2012).
Shakya, R., Szabolcs, M., McCarthy, E., Ospina, E., Basso, K., Nandula, S. et al. The basal-like mammary carcinomas induced by Brca1 or Bard1 inactivation implicate the BRCA1/BARD1 heterodimer in tumor suppression. Proc. Natl Acad. Sci. USA 105, 7040–7045 (2008).
Irminger-Finger, I., Leung, W. C., Li, J., Dubois-Dauphin, M., Harb, J., Feki, A. et al. Identification of BARD1 as mediator between proapoptotic stress and p53-dependent apoptosis. Mol. Cell. 8, 1255–1266 (2001).
Wu, J. Y., Vlastos, A. T., Pelte, M. F., Caligo, M. A., Bianco, A., Krause, K. H. et al. Aberrant expression of BARD1 in breast and ovarian cancers with poor prognosis. Int. J. Cancer 118, 1215–1226 (2006).
Liao, Y., Yuan, S., Chen, X., Zhu, P., Li, J., Qin, L. et al. Up-regulation of BRCA1-associated RING domain 1 promotes hepatocellular carcinoma progression by targeting Akt signaling. Sci. Rep. 7, 7649 (2017).
Zhang, Y. Q., Pilyugin, M., Kuester, D., Leoni, V. P., Li, L., Casula, G. et al. Expression of oncogenic BARD1 isoforms affects colon cancer progression and correlates with clinical outcome. Br. J. Cancer 107, 675–683 (2012).
Pilyugin, M., Descloux, P., Andre, P. A., Laszlo, V., Dome, B., Hegedus, B. et al. BARD1 serum autoantibodies for the detection of lung cancer. PLoS ONE 12, e0182356 (2017).
We wish to thank Yukimi Hashidume-Itoh for handling urine samples and Takako Onodera for data management of patients enrolled in this study (Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences). We are grateful to our clinical colleagues who assisted in sample collection.
Ethics approval and consent to participate
The study protocol was approved by the ethics committee at each participating institution (Institutional Review Board at Nagoya City University Hospital, Institutional Review Board at Nagoya Daini Red Cross Hospital and Ethical Committee at Okazaki Public Health Center), and was conducted according to the ethical guidelines of the Helsinki Declaration of 1964 and later versions. All patients provided written, informed consent prior to enrolment in the study.
The data that support the findings of this study are available on request from the corresponding author (T.S.).
The authors declare no competing interests.
This study was supported, in part, by Japan Agency for Medical Research and Development under Grant Number JP19lm0203005j0003 (to T.S.) and the Takeda Science Foundation (to T.S.).
Note This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Shimura, T., Dayde, D., Wang, H. et al. Novel urinary protein biomarker panel for early diagnosis of gastric cancer. Br J Cancer (2020). https://doi.org/10.1038/s41416-020-01063-5